Biphenyl compounds useful as muscarinic receptor antagonists
This invention provides methods of using compounds of formula Ib below to treat pulmonary disorders. wherein: R 4 is hydrogen or (1-4C)alkyl; q is 0, 1, or 2; R 5 is independently selected from halo, (1-4C)alkyl, and (1-4C)alkoxy, wherein each alkyl and alkoxy group is optionally substituted with from 1 to 3 fluoro substituents; R 7 is hydrogen or (1-4C)alkyl; or a pharmaceuticallly acceptable salt thereof.
1. A method of producing bronchodilation in a patient, the method comprising administering to a patient a bronchodilation-producing amount of a compound of formula Ib:
wherein:
R 4 is hydrogen or (1-4C)alkyl;
q is 0, 1 or 2;
R 5 is independently selected from halo, (1-4C)alkyl and (1-4C)alkoxy, wherein each alkyl and alkoxy group is optionally substituted with from 1 to 3 fluoro substituents;
R 7 is hydrogen or (1-4C)alkyl;
or a pharmaceutically acceptable salt thereof.
2. A method of treating chronic obstructive pulmonary disease or asthma, the method comprising administering to a patient a therapeutically effective amount of a compound of formula Ib:
wherein:
R 4 is hydrogen or (1-4C)alkyl;
q is 0, 1 or 2;
R 5 is independently selected from halo, (1-4C)alkyl and (1-4C)alkoxy, wherein each alkyl and alkoxy group is optionally substituted with from 1 to 3 fluoro substituents;
R 7 is hydrogen or (1-4C)alkyl;
or a pharmaceutically acceptable salt thereof.